https://blueblood.com.tw/wp-content/uploads/2024/09/dna-genetic-biotechnology-science-with-scientist-rsquo-s-hands-disruptive-technology-remix.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302013-05-01 12:00:492025-08-28 10:03:58BBACN composition for antibacterial and anti-inflammatory applications received South Korea patent approval.
https://blueblood.com.tw/wp-content/uploads/2025/03/carbon-nanotubes-nanotechnology-3d-rendering-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302013-05-01 12:00:212025-08-28 10:09:54NEGF preclinical trial project approved by the Ministry of Economic Affairs, receiving NT$27 million under the ‘Promoting Industrial Innovation R&D Program.’
https://blueblood.com.tw/wp-content/uploads/2024/09/dna-genetic-biotechnology-science-with-scientist-rsquo-s-hands-disruptive-technology-remix.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302013-03-01 12:00:482025-08-28 10:10:24Collaborated with the US CRL laboratory to conduct 28-day repeated dose toxicity tests on miniature pigs.
BBACN composition for antibacterial and anti-inflammatory applications received South Korea patent approval.
NEGF preclinical trial project approved by the Ministry of Economic Affairs, receiving NT$27 million under the ‘Promoting Industrial Innovation R&D Program.’
Collaborated with the US CRL laboratory to conduct 28-day repeated dose toxicity tests on miniature pigs.